Pharmacological characterization, structural studies, and in vivo activities of anti-chagas disease lead compounds derived from tipifarnib

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4914-4921

  Buckner, Frederick S ^a   Bahia, Maria Terezinha ^b   Suryadevara, Praveen Kumar ^a   White, Karen L ^c   Shackleford, David M ^c   Chennamaneni, Naveen Kumar ^a   Hulverson, Matthew A ^a   Laydbak, Joy U ^a   Chatelain, Eric ^d   Scandale, Ivan ^d   Verlinde, Christophe L M J ^a   Charman, Susan A ^c   Lepesheva, Galina I ^e   Gelb, Michael H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^c MONASH UNIVERSITY   (Australia)

^d Drugs for Neglected Diseases Initiative   (Switzerland)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; POSACONAZOLE; STEROL 14ALPHA DEMETHYLASE; TIPIFARNIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PARASITEMIA; PLASMA CLEARANCE; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

14-ALPHA DEMETHYLASE INHIBITORS; ADMINISTRATION, ORAL; ALKYL AND ARYL TRANSFERASES; ANIMALS; CHAGAS DISEASE; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MICE; MODELS, MOLECULAR; NITROIMIDAZOLES; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84865422539     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06244-11     Document Type: Article

References (30)

1. Bern C. 2011. Antitrypanosomal therapy for chronic Chagas' disease. N. Engl. J. Med. 364:2527-2534.
2. Buckner FS, Verlinde CLMJ, La Flamme AC, Van Voorhis WC. 1996. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase. Antimicrob. Agents Chemother. 40:2592-2597. (Pubitemid 26367650)
3. Caldas S, et al. 2008. Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole. Exp. Parasitol. 118:315-323. (Pubitemid 351174143)
4. Clayton J. 2010. Chagas disease: pushing through the pipeline. Nature 465:S12-S15.
5. Cohen SJ, et al. 2003. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 21:1301-1306. (Pubitemid 46606407)
6. Collaborative Computational Project N4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760-763.
7. Coura JR, Vinas PA. 2010. Chagas disease: a new worldwide challenge. Nature 465:S6-S7.
8. Cummings KL, Tarleton RL. 2003. Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol. Biochem. Parasitol. 129:53-59. (Pubitemid 36703222)
9. Docampo R. 1981. Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Mol. Biochem. Parasitol. 3:169-180.
10. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132. (Pubitemid 41742764)
11. Hucke O, Gelb MH, Verlinde CL, Buckner FS. 2005. The protein farnesyltransferase inhibitor tipifarnib as a new lead for the development of drugs against Chagas disease. J. Med. Chem. 48:5415-5418. (Pubitemid 41209239)
12. Kraus JM, et al. 2010. Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J. Med. Chem. 53:3887-3898.
13. Kraus JM, et al. 2009. Rational modification of a candidate cancer drug for use against Chagas disease. J. Med. Chem. 52:1639-1647.
14. LaPlante SR, Edwards PJ, Fader LD, Jakalian A, Hucke O. 2011. Revealing atropisomer axial chirality in drug discovery. ChemMedChem 6:505-513.
15. Lepesheva GI, et al. 2010. Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi. J. Biol. Chem. 285:25582-25590.
16. Lepesheva GI, Nes WD, Zhou W, Hill GC, Waterman MR. 2004. CYP51 from Trypanosoma brucei is obtusifoliol-specific. Biochemistry 43:10789-10799. (Pubitemid 39096721)
17. Lepesheva GI, et al. 2010. Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections. J. Biol. Chem. 285:1773-1780.
18. Leslie M. 2011. Infectious diseases. A tropical disease hits the road. Science 333:934.
19. Lewis DF. 2004. 57 varieties: the human cytochromes P450. Pharmacogenomics 5:305-318. (Pubitemid 38499969)
20. Molina J, et al. 2000. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother. 44:150-155. (Pubitemid 30010686)
21. Moser DR, Kirchhoff LV, Donelson JE. 1989. Detection of Trypanosoma cruzi by DNA amplification using the polymerase chain reaction. J. Clin. Microbiol. 27:1477-1482. (Pubitemid 19170146)
22. Otwinowski Z, Minor W. 1995. The HKL manual. Yale University Press, New Haven, CT.
23. Stordeur P, et al. 2002. Cytokine mRNA quantification by real-time PCR. J. Immunol. Methods 259:55-64. (Pubitemid 33124384)
24. Strushkevich N, Usanov SA, Park HW. 2010. Structural basis of human CYP51 inhibition by antifungal azoles. J. Mol. Biol. 397:1067-1078.
25. Suryadevara PK, et al. 2009. Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J. Med. Chem. 52:3703-3715.
26. Urbina JA. 2009. Ergosterol biosynthesis and drug development for Chagas disease. Mem. Inst. Oswaldo Cruz 104(Suppl 1):311-318.
27. Urbina JA. 2010. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 115:55-68.
28. Urbina JA, et al. 1996. Cure of short- and long-term experimental Chagas'disease using D0870. Science 273:969-971. (Pubitemid 26275176)
29. Venet M, End D, Angibaud P. 2003. Farnesyl protein transferase inhibitor ZARNESTRA R115. Curr. Top. Med. Chem. 3:1095-1102.
30. Zujewski J, et al. 2000. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 18:927-941. (Pubitemid 30106625)